IBI3005

DRUG2 trials

Sponsors

Innovent Biologics (Suzhou) Co. Ltd.

Conditions

Locally Advanced or Metastatic Solid TumorsSolid TumorUnresectable

Phase 1

Study of IBI3005 in Subjects With Unresectable, Locally Advanced or Metastatic Solid Tumors

RecruitingNCT06418061

Innovent Biologics (Suzhou) Co. Ltd.Locally Advanced or Metastatic Solid Tumors, Unresectable

Start: 2025-01-08End: 2027-12-31Target: 198Updated: 2025-01-22

Study of IBI3005 Combination Therapy in Participants With Unresectable, Locally Advanced or Metastatic Solid Tumors

Not yet recruitingNCT07612137

Innovent Biologics (Suzhou) Co. Ltd.Solid Tumor

Start: 2026-06-01End: 2028-06-30Target: 282Updated: 2026-05-28